Data from pharmawand - Curated by Toby Galbraith - Date added 03 August 2012

Lundbeck A/S and Otsuka Pharmaceutical Co., Ltd. have announced receipt of a Complete Response Letter from the FDA to the New Drug Application (NDA) for the investigational intramuscular (IM) depot formulation of Abilify (aripiprazole). In the letter, the only issue FDA cited was deficiencies from a recent inspection of a third-party supplier of sterile water.


You will need to login, to leave a comment.

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.


Epidemiology, pathophysiology, diagnosis/treatment guidelines, recent publication summaries and more

Visit Hypogonadism

Cystic Fibrosis

View disease awareness information, treatment options and European Cystic Fibrosis Society best practice guidelines

Visit Cystic Fibrosis

Related Content